Recent approaches in standardization of cardiac markers.
The development of commercial assays for the determination of new cardiac proteins has been one of the most important innovations in the field of cardiovascular diagnostics in the last decade. This significant and sudden advancement has however led to some analytical and interpretative problems. There are problems in test standardization, imprecision, interference and preanalytical variability. We also need to standardize utilization of biomarkers in diagnosis and management of acute cardiac syndromes and clearly define decision thresholds. Powerful tests, such as cardiac markers, on which critical decisions will rest, need highly reliable methods. The feeling is that some assays are inadequately appraised prior to their introduction in clinical use. More studies are needed to implement new devices in the laboratory routine, and only well documented assays should be used in hospital-based laboratories. The technology to address many analytic problems is at hand, but commitment on the part of manufacturers and their customers in the laboratory community is essential.
Panteghini
M
M
Laboratorio Analisi Chimico Cliniche 1, Azienda Ospedaliera Spedali Civili, Brescia, Italy. panteghi@bshosp.unibs.it
D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D006331:Heart Diseases / Q000175:diagnosis* / Q000378:metabolism*; D006801:Humans; D007118:Immunoassay; D012015:Reference Standards
D015415:Biomarkers